Design of Novel Mixer and Applicator for Two-Component Surgical Adhesives

Current mixer and applicator devices on the market are not able to properly and efficiently mix two-component surgical adhesives in small volumes necessary to achieve economic viability. Furthermore, in these devices a significant amount of adhesive is wasted during the application process, as material within the dead space of the mixing chamber must be discarded. We have designed and demonstrated a new active mixer and applicator system capable of rapidly and efficiently mixing two components of an adhesive and applying it to the surgical site. Recently, Messersmith et al. have developed a tissue adhesive inspired by the mussel byssus and have shown that it is effective as a surgical sealant, and is especially suited for wet environments such as in fetal surgery. Like some other tissue sealants, this one requires that two components of differing viscosities be thoroughly mixed within a specified and short time period. Through a combination of compression and shear testing, we demonstrated that our device could effectively mix the adhesive developed by Messersmith et al. and improve its shear strength to significantly higher values than what has been reported for vortex mixing. Overall, our mixer and applicator system not only has potential applications in mixing and applying various adhesives in multiple surgical fields but also makes this particular adhesive viable for clinical use

Design of Novel Mixer and Applicator for Two-Component Surgical Adhesives

Current mixer and applicator devices on the market are not able to properly and efficiently mix two-component surgical adhesives in small volumes necessary to achieve economic viability. Furthermore, in these devices a significant amount of adhesive is wasted during the application process, as material within the dead space of the mixing chamber must be discarded. We have designed and demonstrated a new active mixer and applicator system capable of rapidly and efficiently mixing two components of an adhesive and applying it to the surgical site. Recently, Messersmith et al. have developed a tissue adhesive inspired by the mussel byssus and have shown that it is effective as a surgical sealant, and is especially suited for wet environments such as in fetal surgery. Like some other tissue sealants, this one requires that two components of differing viscosities be thoroughly mixed within a specified and short time period. Through a combination of compression and shear testing, we demonstrated that our device could effectively mix the adhesive developed by Messersmith et al. and improve its shear strength to significantly higher values than what has been reported for vortex mixing. Overall, our mixer and applicator system not only has potential applications in mixing and applying various adhesives in multiple surgical fields but also makes this particular adhesive viable for clinical use

Inhibition of the NOD-Like Receptor Protein 3 Inflammasome Is Protective in Juvenile Influenza A Virus Infection

Influenza A virus (IAV) is a significant cause of life-threatening lower respiratory tract infections in children. Antiviral therapy is the mainstay of treatment, but its effectiveness in this age group has been questioned. In addition, damage inflicted on the lungs by the immune response to the virus may be as important to the development of severe lung injury during IAV infection as the cytotoxic effects of the virus itself. A crucial step in the immune response to IAV is activation of the NOD-like receptor protein 3 (NLRP3) inflammasome and the subsequent secretion of the inflammatory cytokines, interleukin-1β (IL-1β), and interleukin-18 (IL-18). The IAV matrix 2 proton channel (M2) has been shown to be an important activator of the NLRP3 inflammasome during IAV infection. We sought to interrupt this ion channel-mediated activation of the NLRP3 inflammasome through inhibition of NLRP3 or the cytokine downstream from its activation, IL-1β. Using our juvenile mouse model of IAV infection, we show that inhibition of the NLRP3 inflammasome with the small molecule inhibitor, MCC950, beginning 3 days after infection with IAV, improves survival in juvenile mice. Treatment with MCC950 reduces NLRP3 levels in lung homogenates, decreases IL-18 secretion into the alveolar space, and inhibits NLRP3 inflammasome activation in alveolar macrophages. Importantly, inhibition of the NLRP3 inflammasome with MCC950 does not impair viral clearance. In contrast, inhibition of IL-1β signaling with the IL-1 receptor antagonist, anakinra, is insufficient to protect juvenile mice from IAV. Our findings suggest that targeting the NLRP3 inflammasome in juvenile IAV infection may improve disease outcomes in this age group